Ponaxen (Ponatinib) treats blood cancer, with an overall survival rate of 80.5%. Once daily convenient dose. ponatinix manufactured by Everest pharma.
FAQ about Ponaxen (Ponatinib)
Q: What is Ponaxen (Ponatinib) use for?
It is a treatment for some types of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
Q: What generation is ponatinib?
Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Q: Is ponatinib a chemotherapy drug?
Ponatinib is not a chemotherapy drug but one of many “targeted therapies.”About 100 years of research dedicated to understanding the differences between cancer cells and normal cells has resulted in targeted therapy.
Q: How effective is ponatinib?
The ponatinib initial daily dose was 45 mg in 60% of patients, 30 mg in 38% and 15 mg in 2% of patients. After a median time of 12 months, 85% of patients achieved a better molecular response compared with the baseline. Among them, 10 (40%) patients achieved a deep molecular response. No AOEs were observed (Table 2)
Ponaxen (Ponatinib), is an oral drug under the generic of Ponatinib, for the first-line therapy of the people affected with chronic myelogenous leukemia.
It is a highly potential and multi-targeted third generation Bcr-Abl tyrosine-kinase inhibitors (TKI) which is indicated for the adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) or Ph+ALL for those who have no other TKI therapy.
It is also indicated for the adult patients with T315I-positive CML (chronic phase, accelerated phase of blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL).
|Available Pack Size